Novo Nordisk is gaining ground on Eli Lilly in the obesity drug market despite a 12.6% quarterly and 15% yearly drop in Ozempic sales to DKK 27.83 billion in Q1. The recent FDA approval of Wegovy HD, which matches Eli Lilly's Zepbound in weight-loss efficacy, and promising clinical data on new drugs UBT251 and zenagamtide, enhance Novo Nordisk's investment appeal. This suggests potential growth opportunities despite current challenges in their insulin franchise and Ozempic demand decline.
Novo Resources Corp has completed the second tranche of an A$8.2 million placement, raising about C$1.93 million to accelerate drilling and exploration at its Pilbara and Victorian gold projects. The second tranche involved issuing units to Canadian ...
Novo Nordisk's investor relations highlighted that the launch of its oral semaglutide is progressing with dose escalation patterns differing from its injectable forms. Despite improved data capture at 65%, 90% of prescriptions are still paid out-of-p...
Novo Resources Corp. has completed the second tranche of its placement, raising approximately C$1.93 million (A$1.95 million) through the issuance of common shares and options to investors in Canada and overseas. This follows shareholder approval at ...
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and begin covering Lilly's new obesity pill Foundayo from June 1 on its standard drug plans. This move balances coverage between Eli Lilly and Novo Nord...
Novo Resources Corp has regained full control of the Egina Gold Project in Western Australia's Pilbara region after Northern Star Resources withdrew from their earn-in agreement. Northern Star decided not to proceed with the additional A$18 million e...
